文献速递免疫规划卫生政策与健康促进

澳大利亚阿斯利康COVID-19疫苗风险获益分析的贝叶斯网络建模框架

Risk-benefit analysis of the AstraZeneca COVID-19 vaccine in Australia using a Bayesian network modelling framework.
PubMed 文献 · Vaccine · 2021-11-04

该研究用贝叶斯网络整合本地与国际数据、政府报告、文献及专家意见,比较阿斯利康COVID-19疫苗相关血栓形成伴血小板减少综合征(TTS)死亡与不同传播场景下COVID-19死亡预防数。模型估计在≥70岁人群中每百万人接种可预防的COVID-19死亡在高传播下远高于TTS死亡。

要点

  • 澳大利亚报告首剂后TTS发生率低于3/100,000,病死率5-6%。
  • 模型可快速更新数据,适应不同年龄、性别、传播场景和变异株。
  • 高传播下阿斯利康疫苗预防的死亡数远超TTS死亡数(8至>4500倍,随年龄变化)。

核心结论

  • 在澳大利亚,阿斯利康COVID-19疫苗相关TTS风险与获益因年龄组和传播水平而异,高传播下预防死亡数远超TTS死亡数。

研究设计与样本

  • 贝叶斯网络模型整合本地与国际数据、政府报告、已发表文献和专家意见,估计不同年龄、性别、传播水平等场景下的结局概率。

主要发现

  • 在≥70岁人群中,每百万人70%接种首剂、35%接种两剂时,模型估计TTS死亡<1例,低传播下预防25例COVID-19死亡,高传播下预防>3000例死亡。
  • 高传播下,阿斯利康疫苗预防的死亡数远超TTS死亡数,为8至>4500倍(随年龄变化)。
  • 死于COVID-19相关非典型严重血凝块(脑静脉窦血栓和门静脉血栓)的概率比死于TTS高58-126倍(随年龄和性别变化)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Thrombosis and Thrombocytopenia Syndrome (TTS) has been associated with the AstraZencea (AZ) COVID-19 vaccine (Vaxzevria). Australia has reported low TTS incidence of < 3/100,000 after the first dose, with case fatality rate (CFR) of 5-6%. Risk-benefit analysis of vaccination has been challenging because of rapidly evolving data, changing levels of transmission, and variation in rates of TTS, COVID-19, and CFR between age groups. We aim to optimise risk-benefit analysis by developing a model that enables inputs to be updated rapidly as evidence evolves. A Bayesian network was used to integrate local and international data, government reports, published literature and expert opinion. The model estimates probabilities of outcomes under different scenarios of age, sex, low/medium/high transmission (0.05%/0.45%/5.76% of population infected over 6 months), SARS-CoV-2 variant, vaccine doses, and vaccine effectiveness. We used the model to compare estimated deaths from AZ vaccine-associated TTS with i) COVID-19 deaths prevented under different scenarios, and ii) deaths from COVID-19 related atypical severe blood clots (cerebral venous sinus thrombosis & portal vein thrombosis). For a million people aged ≥ 70 years where 70% received first dose and 35% received two doses, our model estimated < 1 death from TTS, 25 deaths prevented under low transmission, and > 3000 deaths prevented under high transmission. Risks versus benefits varied significantly between age groups and transmission levels. Under high transmission, deaths prevented by AZ vaccine far exceed deaths from TTS (by 8 to > 4500 times depending on age). Probability of dying from COVID-related atypical severe blood clots was 58-126 times higher (depending on age and sex) than dying from TTS. To our knowledge, this is the first example of the use of Bayesian networks for risk-benefit analysis for a COVID-19 vaccine. The model can be rapidly updated to incorporate new data, adapted for other countries, extended to other outcomes (e.g., severe disease), or used for other vaccines.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Lau CL, Mayfield HJ, Sinclair JE, et al. Risk-benefit analysis of the AstraZeneca COVID-19 vaccine in Australia using a Bayesian network modelling framework. Vaccine. 2021. PMID: 34810000. doi:10.1016/j.vaccine.2021.10.079

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。